NaturalShrimp, Inc. announced the completion at the end of February 2024 of a successful 6-month trial in Japan with its patented electrocoagulation technology for growing high-quality shrimp in aquatic recirculating systems (RAS).
NaturalShrimp and the Hydrenesis biotechnology team started using the Electrocoagulation (EC) and Hydrogas™ technologies one week after arriving at the Japanese shrimp research facility.
The trial consisted of comparing a tank treated by the EC and Hydrogas™ with a tank treated by a traditional biofilter. The first removed the ammonia from the water and consequently, the shrimp growth rate was increased.
According to the company, the Japanese team at the facility was able to collect data under varying conditions by testing different flow rates, ammonia levels, and amperage levels. Now, Natural Shrimp is looking for a partnership, license, or business combination in Japan.
Regarding these plans, Tom Untermeyer, Natural Shrimp's Chief Technology Officer said: "The Japanese market is uniquely set up for the NSI technology based on its current shrimp import conditions and a robust consumption of shrimp as a primary protein source. I am excited to see where this will lead us in the future with the hope of helping them and others develop successful shrimp production systems using our technologies."